Zobrazeno 1 - 10
of 136
pro vyhledávání: '"EFV 400 mg"'
Autor:
Xu, Ling1 (AUTHOR), Peng, Wenxiu2 (AUTHOR), Song, Xiaojing1 (AUTHOR), Li, Yanling1 (AUTHOR), Han, Yang1 (AUTHOR), Zhu, Ting1 (AUTHOR), Fu, Qiang2 (AUTHOR), Du, Xiaoli2 (AUTHOR), Cao, Wei1 (AUTHOR), Li, Taisheng1,3,4 (AUTHOR) litsh@263.net
Publikováno v:
BMC Infectious Diseases. 2/17/2021, Vol. 21 Issue 1, p1-9. 9p.
Autor:
Ling Xu, Wenxiu Peng, Xiaojing Song, Yanling Li, Yang Han, Ting Zhu, Qiang Fu, Xiaoli Du, Wei Cao, Taisheng Li
Publikováno v:
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-9 (2021)
Abstract Background The plasma concentration of patients treated with efavirenz (EFV) 600 mg was found to exceed the upper limit of the proposed therapeutic window in most Chinese HIV-infected individuals; thus, dosage reduction of EFV to 400 mg dail
Externí odkaz:
https://doaj.org/article/c426d6bb611a401f8bfdc13af982ff8b
Autor:
Yanling Li, Yang Han, Ling Xu, Wenxiu Peng, Taisheng Li, Qiang Fu, Xiaoli Du, Ting Zhu, Wei Cao, Xiaojing Song
Publikováno v:
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-9 (2021)
BMC Infectious Diseases
BMC Infectious Diseases
Background The plasma concentration of patients treated with efavirenz (EFV) 600 mg was found to exceed the upper limit of the proposed therapeutic window in most Chinese HIV-infected individuals; thus, dosage reduction of EFV to 400 mg daily warrant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ed8616e5bdd00ef448b0730658a1e70
https://doaj.org/article/c426d6bb611a401f8bfdc13af982ff8b
https://doaj.org/article/c426d6bb611a401f8bfdc13af982ff8b
Autor:
Wang, Ran, Sun, Lijun, Wang, Xi, Zhai, Yuanyi, Wang, Lijing, Ma, Ping, Wu, Cuisong, Zhou, Yingquan, Chen, Renfang, Wang, Rugang, Zhang, Fengchi, Hua, Wei, Li, Aixin, Xia, Wei, Gao, Yue, Li, Rui, Lv, Shiyun, Shao, Ying, Cao, Yu, Zhang, Tong
Publikováno v:
Clinical Infectious Diseases; 7/15/2024, Vol. 79 Issue 1, p169-176, 8p
Autor:
Gedefaw, Abel1,2 (AUTHOR) abel.degefaw.ali@ki.se, Tadesse, Birkneh Tilahun1 (AUTHOR), Berhan, Yifru3 (AUTHOR), Makonnen, Eyasu4,5 (AUTHOR), Vella, Stefano2 (AUTHOR), Aklillu, Eleni2 (AUTHOR)
Publikováno v:
BMC Infectious Diseases. 9/2/2024, Vol. 24 Issue 1, p1-12. 12p.
Autor:
Xiao, Jing1 (AUTHOR), Xiao, Jiang2,3 (AUTHOR), Liu, Ying2,3 (AUTHOR), Li, Bei2,3 (AUTHOR), Zhang, Leidan1 (AUTHOR), Han, Junyan1,2,4,5 (AUTHOR), Zhao, Hongxin1,2,3 (AUTHOR)
Publikováno v:
International Journal of Infectious Diseases. Apr2022, Vol. 117, p48-55. 8p.
Autor:
Hai Long1, Quanying He2, Yanmei Bi3, Yingchun Ke4, Xiaoxin Xie1, Xiuhong Zhao3, Si Tan5, Yanhe Luo6, Zhong Chen5, Xiaoli Yu6, Linghua Li4 llheliza@126.com
Publikováno v:
BioScience Trends. Apr2024, Vol. 18 Issue 2, p176-186. 11p.
Autor:
Eichbaum, Christine1, Mathes, Kristin1, Burhenne, Jürgen1, Markert, Christoph1, Blank, Antje1, Mikus, Gerd1
Publikováno v:
Basic & Clinical Pharmacology & Toxicology. Feb2015, Vol. 116 Issue 2, p129-133. 5p.
Publikováno v:
International Journal of Infectious Diseases, Vol 117, Iss , Pp 48-55 (2022)
Background: Efavirenz (EFV) 400 mg has been recommended to replace EFV 600 mg. There are only 200 mg and 600 mg dosage forms of EFV in China. Whether switching from one-tablet EFV 600 mg to two-tablet EFV 200 mg would weaken adherence or further affe
Externí odkaz:
https://doaj.org/article/5191498f31ae4737ab8a10f87c18b06a
Autor:
ARORA, SUMIT1, ASHTA, KULDEEP K.2, ANILKUMAR, ANIRUDH3 anirudhanilkumar7@gmail.com, RAMAN, NISHANT4
Publikováno v:
Current Medicine Research & Practice. Sep/Oct2023, Vol. 13 Issue 5, p209-216. 10p.